Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

Merck, Schering Reach Vytorin Settlement

Posted by Chrissie Cole
Wednesday, August 05, 2009 7:49 PM EST
Category: Major Medical
Tags: FDA and Prescription Drugs, Drug Products, Zytorin, Zetia, Cholesterol Drugs, Merck, Schering-Plough


IMAGE SOURCE: © iStockphoto/ cholesterol lowering drugs/ author: dlerick

Merck & Co. and Schering-Plough will pay $41.5 million to settle class-action lawsuits filed by patients taking their shared cholesterol drugs Vytorin and Zetia, the companies said Wednesday.

The joint venture, Merck/Schering-Plough Pharmaceuticals (MSP), recorded these charges in the second quarter 2009 to cover the settlement's cost, a spokesman for Merck said.

The lawsuits involved allegations stemming from the Enhance clinical trial, whose results in January 2008 cast doubt on the efficacy of Zetia (ezetimibe) and Vytorin (simvastatin).

Vytorin is a combination drug made up of Merck’s Zocor, a statin drug, and Schering-Plouugh’s Zetia, a newer cholesterol lowering drug.

The settlement resolves some 145 lawsuits pending in U.S. District Court for the District of New Jersey that were seeking class-action status to represent consumers and insurers who purchased, used or paid money toward the purchase of Vytorin or Zetia.

The settlement is not an admission of liability or misconduct in connection with the marketing or sale of Vytorin or Zetia or plaintiffs' allegations relating to the Enhance study.

The agreement involves two settlements - one with insurers and the other with consumers who purchased, used or paid money toward the purchase of Vytorin and Zetia. The consumer settlements require court approval.

The Enhance study found Vytorin was no better at reducing plaque buildup then generic brand Zocor which has been on the market for more than two years.

In July, the companies agreed to pay $5.4 million to 35 states to settle claims they had violated consumer-protection laws by delaying negative findings from the Enhance study.

Zytorin was approved by the Food and Drug Administration in 2002, on the basis of drug trials involving 3,900 patients for 12 weeks, not long enough to determine if the drug reduced heart attacks or cardiovascular disease. #


Anonymous User
Posted by JILL PAUL RN
Wednesday, August 05, 2009 8:30 PM EST

Chrissie, a settlement of 41.5 million for a drug that didn't reduce cholesterol! Cholesterol is something that can be monitored by lab work and if the drug is not working, can be changed very easily for another. What if you had a defective medical device implanted in you at great expense and it failed through no fault of your own? This is the reason why I am such a strong advocate of The Medical Device Safety Act. These injured people have no where to turn and the medical device manufacturers' will not accept reponsibility for their own products. The meeting in Washington yesterday on MDSA left me quite disgusted with those not in favor of the bill. All I can say is that they must be in someone's hip pocket and should be investigated by the Attorney's. I did see the video in its entirety.

Posted by Chrissie Cole
Wednesday, August 05, 2009 11:09 PM EST

Jill, I agree with you wholeheartedly. The more I read about MDSA, the more I just don't understand how people aren't *MORE* supportive.

I very much enjoy reading all of your helpful and informative comments! Thank you!

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address


RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes